Equibles does not estimate personal net worth.
Barry Quart was last confirmed as Board Member at Heron Therapeutics, Inc. (HRTX) in a filing dated May 1, 2023. Earlier roles on record: CEO, Chairman and Board Member at Heron Therapeutics, Inc. (HRTX) until April 3, 2023. Heron Therapeutics, Inc. reported in an 8-K filed April 3, 2023 that Barry Quart resigned as Chief Executive Officer, effective April 3, 2023. Heron Therapeutics, Inc. reported in an 8-K filed April 3, 2023 that Barry Quart resigned as director, effective April 3, 2023. Heron Therapeutics, Inc. reported in an 8-K filed April 3, 2023 that Barry Quart resigned as Chairman, effective April 3, 2023. The proxy statement of Heron Therapeutics, Inc. reports total compensation of $1,145,704 for Barry Quart in fiscal 2022, including a base salary of $736,000. Disclosed compensation is on record for 6 fiscal years. Barry Quart has spoken on 5 earnings calls across 1 company, most recently for Heron Therapeutics, Inc. on January 9, 2023. The companies whose calls Barry Quart spoke on are classified in the Healthcare sector.
“Mr. Collard succeeds Barry Quart, who will cease to serve as the Company’s Chairman, Chief Executive Officer and a director as of the Effective Date.”
“Mr. Collard succeeds Barry Quart, who will cease to serve as the Company’s Chairman, Chief Executive Officer and a director as of the Effective Date.”
“For those who are wondering why this call is later in the month than usual, we are currently not an accelerated filer, and we wanted to give our newly reconstituted Board of Directors the opportunity to get to know the company before closing the quarter.”
“The third quarter has been productive on a number of fronts and disappointing on others. We're obviously delighted with the approval of APONVIE, our fourth commercial product.”
“The second quarter has been extremely productive on a number of fronts. John will discuss details regarding our two commercial franchises, both of which showed good growth in the second quarter, beating consensus estimates.”
“The first quarter was a major turning point for the commercialization of ZYNRELEF with the official rollout of expanded indications obtained mid-December.”
“2021 was one of the most important and productive years in our company’s history. We obtained initial approval and successfully launched ZYNRELEF for postoperative pain in the United States.”
2020-10-13–2023-04-03
2013-01-01–2023-04-03
Start not stated–2023-05-01
Last confirmed by a filing; no departure on record
Start not stated–2023-04-03
Biotechnology · Healthcare
Board Member, CEO, Chairman
2013-01-01–2023-04-03
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Heron Therapeutics, Inc. (HRTX) | Pharm.D. Former Chief Executive Officer | $736,000 | $1,145,704 |
| 2021 | Heron Therapeutics, Inc. (HRTX) | Pharm.D. Former Chief Executive Officer | $700,000 | $5,430,828 |
| 2020 | Heron Therapeutics, Inc. (HRTX) | Pharm.D. Chief Executive Officer | $676,838 | $5,346,803 |
| 2019 | Heron Therapeutics, Inc. (HRTX) | Pharm.D. Chief Executive Officer | $638,991 | $5,870,479 |
| 2018 | Heron Therapeutics, Inc. (HRTX) | Pharm.D. Chief Executive Officer | $614,414 | $5,991,297 |
| 2017 | Heron Therapeutics, Inc. (HRTX) | Pharm.D. President and Chief Executive Officer | $596,518 | $4,243,100 |
